Impacts of Cost Containment Strategies on Pharmaceutical Expenditures of the National Health Insurance in Taiwan, 1996–2003

被引：0
|
作者：
Yue-Chune Lee
Ming-Chin Yang
Yu-Tung Huang
Chien-Hsiang Liu
Sun-Bing Chen
机构：
[1] National Yang-Ming University,Institute of Health and Welfare Policy, College of Medicine
[2] National Taiwan University,Graduate Institute of Health Care Organization Administration, College of Public Health
[3] National Yang-Ming University,Division of Health Welfare Policy and Management, Institute of Public Health, College of Medicine
[4] Bureau of National Health Insurance,Division of Pharmaceutical Affairs
[5] Bureau of National Health Insurance,undefined
来源：
PharmacoEconomics | 2006年 / 24卷
关键词：
National Health Insurance; Severe Acute Respiratory Syndrome; Reference Price; Price Adjustment; Severe Acute Respiratory Syndrome;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Introduction: Pharmaceutical expenditure (PE) of the National Health Insurance (NHI) programme in Taiwan grew from 62.2 billion Taiwan new dollars ($NT) in 1996 to $NT94.5 billion in 2003.The government has been introducing many strategies to control PE since the inception of NHI including price adjustment based on the prices of international products or existing products (inter-brands comparison), or market price and volume survey; delegation of financial responsibility to regional bureaux; co-payment for outpatient drugs; generic grouping (the reference pricing scheme based on chemical equivalence); a global budget payment system for clinics and hospitals; and reduction in the flat daily payment rate of the drugs for clinics. The aim of this study was to evaluate the impact of these cost containment strategies on the PE of the NHI programme from 1996 to 2003.
引用
收藏
页码：891 / 902
页数：11
相关论文
共 50 条
12345